Eurofins expands its leading footprint in biopharmaceutical products testing with the acquisition of ams Laboratories in Australia
Friday, March 11, 2016
Eurofins Scientific (EUFI.PA), the world leader in biopharmaceutical products testing, announces its entry into the biopharmaceutical products testing market in the Asia Pacific region with the acquisition of ams Laboratories Pty Ltd. ("ams Laboratories"), the leading independent analytical and cGMP Quality Control (QC) services provider for biopharmaceutical products and medical devices in Australia.
Founded 20 years ago, ams Laboratories has grown rapidly to become one of the top three, and the largest pure-play biopharmaceutical products testing provider in the domestic market, serving the biopharma and medical devices industries. The company employs 45 staff across its 2 sites in Sydney and Brisbane. In the past decade, it has grown well above Eurofins' annual organic growth objective, and generated revenues in excess of EUR 5m for the fiscal year 2015, the majority of which is from biopharmaceutical products testing. The company is also active in medical device testing, as well as in probiotics and nutraceutical testing.
The acquisition of ams Laboratories provides Eurofins with a strong entry platform to deploy its market-leading biopharmaceutical testing capabilities to support the pharmaceutical and biotechnology industries in the Asia Pacific region. Furthermore, it allows Eurofins to expand into medical device testing in the region, which is entirely complementary to its existing biopharma capabilities. The company therefore presents an excellent geographical and operational fit for the Group. ams Laboratories further expands the Eurofins global biopharma service offering, and will enable the Group to further leverage its existing client relationships in Europe and North America, and accelerate its expanding client reach in Asia Pacific, which still represents a vast potential growth market for drug development.
In return, ams will benefit from access to the complete range of Eurofins' portfolio of services as the global reference in biopharmaceutical testing, which will enable it to expand its service offering and its footprint in the biopharmaceutical and medical device testing markets, as well as in the nutraceutical testing market in the region.
Comment from Dr. Gilles Martin, Eurofins CEO: "The acquisition of ams Laboratories provides Eurofins a platform to deploy its renowned capabilities in biopharmaceutical products testing in the Asia Pacific region, and reinforces the Group's global leadership in the biopharmaceutical products testing market. We look forward to expanding and strengthening ams Laboratories' footprint by providing them access to the full range of Eurofins' capabilities."
For more information, please visit www.eurofins.com or contact:
Eurofins Investor Relations
Phone: +32 2 766 1620
Notes for the editor:
Eurofins - a global leader in bio-analysis
Eurofins Scientific is the world leader in food, environment and pharmaceutical products testing. It is also one of the global market leaders in agroscience, genomics, discovery pharmacology and central laboratory services. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA.
With over 22,000 staff in more than 225 laboratories across 39 countries, Eurofins offers a portfolio of over 130,000 reliable analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group provides its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.
The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific’ management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.